ID Biomedical&#39;s Shot in the Arm
603104
ID Biomedical (Nasdaq: IDBE) recently showed the importance of being in the right place at the right time, especially in the vaccine business.
583813
It takes another run at getting FDA approval for its lead drug.
177673
Hundreds of patients and physicians have contacted a special information line set up by Merck-Israel in the last few days after the international pharmaceutical company voluntarily withdrew Vioxx - one of the world&#39;s most popular arthritis and acute
692911
It recalls a solution that might be linked to a rare infection.
731230
The biotech mines extra value from its compound library.
573459
A key study of its lead drug proceeds faster than expected.
444613
Shares of pharmaceutical companies OSI  Pharmaceuticals Inc. OSIP.O and Genentech Inc. DNA.N fell  sharply before the bell on Friday on concerns about the price  and a warning label on a key new drug the two collaborated to  produce.
665690
The developing biopharmaceutical company announces a share offering.
700955
If the plans of the Turku-based company Biotie Therapies and the Californian Somaxon Pharmaceuticals work out, Americans could soon have access to a new medicine that is claimed to work against different types ...
737440
An unsurprising response from the FDA.
17093
ID Biomedical Corp. (IDB.TO: Quote, Profile, Research) (IDBE.O: Quote, Profile, Research) signed a 10-year US distribution deal for its Fluviral drug that could reap
631685
With the closure of IETF&#39;s MARID group a month ago, many of us have left Microsoft&#39;s Sender-ID standard for the dead. After being rejected by the Apache Foundation and the Debian Project over licensing issues
457614
One of the nation&#39;s leading cardiovascular medical researchers has issued a call for less aggressive direct-to-consumer advertising and better safety assurances of medications in a special article posted online today by JAMA because of its relevance to
325918
At least that&#39;s what NABI Biopharmaceuticals (Nasdaq: NABI) suggests based on the results of a small phase 2 trial with the drug NicVAX that was released yesterday.
507533
ID Biomedical Corp. IDB.TO IDBE.O  signed a 10-year U.S. distribution deal for its Fluviral drug  that could reap sales of $2.3 billion and help U.S. authorities  fill a flu vaccine shortage, the company said on Monday.
79317
This has not been an especially good year for regulatory government agencies, with their accompanying acronyms. Let&#39;s begin with the Food and Drug Administration (FDA), which can&#39;t quite make up its mind which drug will kill us first - or how quickly.
421804
Abbott Laboratories Inc. ABT.N is  betting $1 billion in deals and the start of a new clinical  trial will finally get Wall Street to focus on its  cardiovascular device business.